Stroke, Acute Ischemic Clinical Trial
Official title:
A Phase Ib Dose-Escalation Study of Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke Patients
The purpose of this study is to investigate the safety and feasibility of intra-arterial albumin infusion for patients with acute ischemic stroke after successful thrombectomy and to further explore the optimal dose of albumin through the implementation of a 3 + 3 dose-escalation design.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | February 29, 2024 |
Est. primary completion date | February 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. AIS patients with anterior circulation due to large vessel occlusion; 2. Age between 18 and 80 years; 3. Baseline NIHSS score = 6; 4 .Successful recanalization after thrombectomy (mTICI grade = 2b); 5. Written informed consent provided by the patients or their legal relatives. . Exclusion Criteria: 1. Upon admission, the patient's medical history and physical examination revealed manifestations indicative of congestive heart failure (CHF), such as jugular venous distention, the presence of a third heart sound, resting tachycardia at a rate of 100 beats per minute attributable to heart failure, hepatomegaly, and/or lower extremity edema attributable to heart failure or of unknown etiology; 2. History of acute myocardial infarction within the preceding 3 months; 3. The patient's medical history, electrocardiogram findings upon admission, or physical examination indicated the presence of second- or third-degree heart block or any arrhythmia associated with hemodynamic instability, as determined by the investigator's assessment; 4. Acute or chronic renal failure with serum creatinine levels exceeding 2.0 mg/dL; 5. Severe anemia characterized by a hematocrit below 32%; 6. Computed tomography findings upon admission indicating the presence of any form of hemorrhage; 7. Pregnancy status; 8. Previous history of allergic reactions to albumin administration; 9. Elevated blood pressure exceeding 185/110 mmHg when investigating the use of albumin administration; 10. Presence of other potentially life-threatening medical conditions; 11. Individuals with current chronic lung diseases, such as chronic obstructive pulmonary disease, bronchiectasis, or any other lung disorder that significantly impairs daily activities; 12. Individuals with known allergies to albumin. |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Huanhu Hospital | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin Huanhu Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with major response | Major response is any of the following:
Any forms of Intracranial hemorrhage; Pulmonary edema; Heart failure; Skin itching, dyspnea and other allergic symptoms; Death of any causes. |
7 days after initiation of infusion of albumin intra-arterially. |